search
Back to results

Quantification of Elastin Markers Synthesis in Williams-Beuren Syndrome and 7q11.23 Micro-duplication Syndrome (ELAST7)

Primary Purpose

Williams-Beuren Syndrome, Micro-duplication 7q11.23 Syndrome, Vasculopathy

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Physical examination and Urine and blood samples
Urine and blood samples
Sponsored by
Hospices Civils de Lyon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Williams-Beuren Syndrome focused on measuring Williams-Beuren Syndrome, Micro-duplication 7q11.23 syndrome, Vasculopathy

Eligibility Criteria

3 Months - 60 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age : from 3 months to 60 years old
  • Williams Beuren group : Diagnosis confirmed with FISH
  • Micro-duplication 7q11.23 group : Diagnosis confirmed with CGHarray
  • Healthy Group : no cardiovascular and neurological medical history
  • Informed consent

Exclusion Criteria:

  • No social insurance
  • Subject under judicial protection
  • Subject participating in another research including an exclusion period still in progress

Sites / Locations

  • Hôpital Femme Mère Enfant - Hospices Civils de Lyon

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Other

Other

Other

Arm Label

Williams Beuren

Micro-duplication 7q11.23

Healthy Group

Arm Description

Subjects aged from 3 months to 60 years with a diagnosis confirmed with FISH of Williams Beuren syndrome.

Subjects aged from 3 months to 60 years with a diagnosis confirmed with CGHarray of micro-duplication 7q11.23 syndrome.

Subjects without cardiovascular and neurological medical history.

Outcomes

Primary Outcome Measures

Plasma level of elastin peptides (PE)
To quantify plasma level of elastin peptides in participants in order to correlate the levels of these markers with the number of copies of ELN gene (proportional positive relationship "gene copy number - circulating levels of markers). The primary endpoint will be assessed by measuring the blood level of PE between groups
Urinary level of elastin peptides (PE)
To quantify urinary level of elastin peptides in participants in order to correlate the levels of these markers with the number of copies of ELN gene (proportional positive relationship "gene copy number - circulating levels of markers). The primary endpoint will be assessed by measuring the urinary level of PE between groups

Secondary Outcome Measures

Correlation between blood level of PE and cardiovascular involvement in patients.
Blood level of PE will be correlated with the presence / severity of cardiovascular disease
Correlation between urinary level of PE and cardiovascular involvement in patients.
Urinary level of PE will be correlated with the presence / severity of cardiovascular disease
Blood level of PE in treated and untreated minoxidil patients
Blood levels of PE in the samples of patients who participated in the minoxidil clinical trial will be compare to those of participants of this study
Urinary level of PE in treated and untreated minoxidil patients
Urinary levels of PE in the samples of patients who participated in the minoxidil clinical trial will be compare to those of participants of this study

Full Information

First Posted
August 7, 2019
Last Updated
August 8, 2019
Sponsor
Hospices Civils de Lyon
search

1. Study Identification

Unique Protocol Identification Number
NCT04051086
Brief Title
Quantification of Elastin Markers Synthesis in Williams-Beuren Syndrome and 7q11.23 Micro-duplication Syndrome
Acronym
ELAST7
Official Title
Quantification of Elastin Markers Synthesis in Williams-Beuren Syndrome and 7q11.23 Micro-duplication Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Unknown status
Study Start Date
October 2019 (Anticipated)
Primary Completion Date
October 2021 (Anticipated)
Study Completion Date
October 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospices Civils de Lyon

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Introduction: Williams-Beuren syndrome is a rare genetic disorder caused by a 7q11.23 microdeletion. The phenotype associates vasculopathy (arterial stenosis, hypertension), dimorphism and intellectual disability. Microdeletion includes several genes: ELN encodes for elastin and the haplo-insufficiency (only 1 functional copy) causes vasculopathy. The primary objective is to quantify plasma and urinary levels of elastin peptides in Williams-Beuren patients and 7q11.23 micro-duplication syndrome patients in order to correlate the levels of these markers with the number of copies of ELN gene (proportional positive relationship "gene copy number - circulating levels of markers) Materials and Methods: This prospective study will be carried out in Lyon at the "Hôpital Femme-Mère-Enfant" for 2 years. 3 groups of patients will be studied: Williams-Beuren patients (N=20), micro-duplication 7q11.23 syndrome patients (N=10) and healthy patients (N=60). Subjects will be followed for 1 day. Clinical examination (weight, height, blood pressure) and biological sample collection (blood and urine sample) will be carry out for Williams Beuren and micro-duplication 7q11.23 patients group. A large majority of visits will be part of patients' usual care. A large part of patients are systematically seen in consultation once a year. For healthy group, only biological sample collection will be carry out. The PE concentrations will be assessed and compared between the three groups of patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Williams-Beuren Syndrome, Micro-duplication 7q11.23 Syndrome, Vasculopathy
Keywords
Williams-Beuren Syndrome, Micro-duplication 7q11.23 syndrome, Vasculopathy

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
90 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Williams Beuren
Arm Type
Other
Arm Description
Subjects aged from 3 months to 60 years with a diagnosis confirmed with FISH of Williams Beuren syndrome.
Arm Title
Micro-duplication 7q11.23
Arm Type
Other
Arm Description
Subjects aged from 3 months to 60 years with a diagnosis confirmed with CGHarray of micro-duplication 7q11.23 syndrome.
Arm Title
Healthy Group
Arm Type
Other
Arm Description
Subjects without cardiovascular and neurological medical history.
Intervention Type
Biological
Intervention Name(s)
Physical examination and Urine and blood samples
Intervention Description
Only one visit for each participant : A large majority of visits will be part of patients' usual care Medical examination : birth, weight, gender, blood pressure, medical history Urine and blood samples
Intervention Type
Biological
Intervention Name(s)
Urine and blood samples
Intervention Description
Only one visit for each participant Medical history Urine and blood samples
Primary Outcome Measure Information:
Title
Plasma level of elastin peptides (PE)
Description
To quantify plasma level of elastin peptides in participants in order to correlate the levels of these markers with the number of copies of ELN gene (proportional positive relationship "gene copy number - circulating levels of markers). The primary endpoint will be assessed by measuring the blood level of PE between groups
Time Frame
1 day
Title
Urinary level of elastin peptides (PE)
Description
To quantify urinary level of elastin peptides in participants in order to correlate the levels of these markers with the number of copies of ELN gene (proportional positive relationship "gene copy number - circulating levels of markers). The primary endpoint will be assessed by measuring the urinary level of PE between groups
Time Frame
1 day
Secondary Outcome Measure Information:
Title
Correlation between blood level of PE and cardiovascular involvement in patients.
Description
Blood level of PE will be correlated with the presence / severity of cardiovascular disease
Time Frame
1 day
Title
Correlation between urinary level of PE and cardiovascular involvement in patients.
Description
Urinary level of PE will be correlated with the presence / severity of cardiovascular disease
Time Frame
1 day
Title
Blood level of PE in treated and untreated minoxidil patients
Description
Blood levels of PE in the samples of patients who participated in the minoxidil clinical trial will be compare to those of participants of this study
Time Frame
1 day
Title
Urinary level of PE in treated and untreated minoxidil patients
Description
Urinary levels of PE in the samples of patients who participated in the minoxidil clinical trial will be compare to those of participants of this study
Time Frame
1 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Months
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age : from 3 months to 60 years old Williams Beuren group : Diagnosis confirmed with FISH Micro-duplication 7q11.23 group : Diagnosis confirmed with CGHarray Healthy Group : no cardiovascular and neurological medical history Informed consent Exclusion Criteria: No social insurance Subject under judicial protection Subject participating in another research including an exclusion period still in progress
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Massimiliano ROSSI, Dr
Phone
04 27 85 55 72
Ext
+33
Email
Massimiliano.rossi@chu-lyon.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Linda PONS, Dr
Phone
04.27.85.51.43
Ext
+33
Email
linda.pons@chu-lyon.fr
Facility Information:
Facility Name
Hôpital Femme Mère Enfant - Hospices Civils de Lyon
City
Bron
ZIP/Postal Code
69677
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Massimiliano ROSSI, Dr
Phone
04 27 85 55 72
Ext
+33
Email
Massimiliano.rossi@chu-lyon.fr
First Name & Middle Initial & Last Name & Degree
Linda PONS, Dr
Phone
04.27.85.51.43
Ext
+33
Email
linda.pons@chu-lyon.fr
First Name & Middle Initial & Last Name & Degree
Massimiliano ROSSI, Dr
First Name & Middle Initial & Last Name & Degree
Patrick EDERY, Pr
First Name & Middle Initial & Last Name & Degree
Damien SANLAVILLE, Pr
First Name & Middle Initial & Last Name & Degree
Aurélia BERTHOLET-THOMAS, Dr
First Name & Middle Initial & Last Name & Degree
Aurélie PORTEFAIX, Dr
First Name & Middle Initial & Last Name & Degree
Lionel BOUVET, Dr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Quantification of Elastin Markers Synthesis in Williams-Beuren Syndrome and 7q11.23 Micro-duplication Syndrome

We'll reach out to this number within 24 hrs